Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 1 | 0 | 3 | 1 | 0 |
Analyst Firms Making Recommendations1
- Goldman Sachs
- BTIG
- Canaccord Genuity
- JP Morgan
- William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acutus Medical
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/16/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | 501.44% | Goldman Sachs | Amit Hazan | $1 → $1.5 | Maintains | Neutral | Get Alert |
| 06/24/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | 501.44% | BTIG | Marie Thibault | $2 → $1.5 | Maintains | Buy | Get Alert |
| 04/27/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | 701.92% | BTIG | Marie Thibault | → $2 | Upgrade | Neutral → Buy | Get Alert |
| 04/14/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | 300.96% | Goldman Sachs | Amit Hazan | $5 → $1 | Maintains | Neutral | Get Alert |
| 01/20/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | — | BTIG | Marie Thibault | — | Downgrade | Buy → Neutral | Get Alert |
| 01/14/2022 | AFIB | Buy Now | Acutus Medical | $0.25 | 1102.89% | Canaccord Genuity | William Plovanic | $10 → $3 | Downgrade | Buy → Hold | Get Alert |
| 11/12/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | — | JP Morgan | Robbie Marcus | — | Downgrade | Neutral → Underweight | Get Alert |
| 11/12/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | 3909.62% | Canaccord Genuity | William Plovanic | — | Maintains | Buy | Get Alert |
| 10/22/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | 3909.62% | Goldman Sachs | Amit Hazan | — | Initiates | → Neutral | Get Alert |
| 07/15/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | 7117.32% | Canaccord Genuity | William Plovanic | — | Upgrade | Hold → Buy | Get Alert |
| 03/19/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | 6315.4% | Canaccord Genuity | William Plovanic | — | Maintains | Hold | Get Alert |
| 03/19/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | — | William Blair | Margaret Kaczor | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/19/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | 7518.28% | JP Morgan | Robbie Marcus | — | Downgrade | Overweight → Neutral | Get Alert |
| 01/14/2021 | AFIB | Buy Now | Acutus Medical | $0.25 | — | B of A Securities | Bob Hopkins | — | Downgrade | Buy → Neutral | Get Alert |
What is the target price for Acutus Medical (AFIB)?
The latest price target for Acutus Medical (NASDAQ: AFIB) was reported by Goldman Sachs on August 16, 2022. The analyst firm set a price target for $1.50 expecting AFIB to rise to within 12 months (a possible 501.44% upside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acutus Medical (AFIB)?
The latest analyst rating for Acutus Medical (NASDAQ: AFIB) was provided by Goldman Sachs, and Acutus Medical maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Acutus Medical (AFIB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acutus Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acutus Medical was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
Is the Analyst Rating Acutus Medical (AFIB) correct?
While ratings are subjective and will change, the latest Acutus Medical (AFIB) rating was a maintained with a price target of $1.00 to $1.50. The current price Acutus Medical (AFIB) is trading at is $0.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.